An inhibitor of EGFR and ErbB2
Related Products
Alternative(s)
11492Afatinib
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Afatinib (maleate)

Item No. 21567

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2E-butenamide, 2Z-butenedioate (1:2)
CAS Number
850140-73-7
Synonyms
  • Afatinib dimaleate
  • BIBW 2992
  • BIBW 2992MA2
Molecular Formula
C24H25ClFN5O3 • 2C4H4O4
Formula Weight
718.1
Purity
≥95%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 30 mg/mLDMSO: 30 mg/mLPBS (pH 7.2): 10 mg/mL
λmax
253, 345 nm
SMILES
FC(C=C1)=C(Cl)C=C1NC2=NC=NC3=C2C=C(NC(/C=C/CN(C)C)=O)C(O[C@@H]4COCC4)=C3.OC(/C=C\C(O)=O)=O.OC(/C=C\C(O)=O)=O
InChi Code
InChI=1S/C24H25ClFN5O3.2C4H4O4/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15;2*5-3(6)1-2-4(7)8/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29);2*1-2H,(H,5,6)(H,7,8)/b4-3+;2*2-1-/t16-;
InChi Key
USNRYVNRPYXCSP-JUGPPOIOSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    100 mg

    $54

    Add

    250 mg

    $108

    Add

    500 mg

    $203

    Add

    1 g

    $378

    Add
    Kinase Resource Center
    Discover Products & Resources for Kinase Research
    • Kinase inhibitors, screening libraries, assay kits, & more
    • Tools to study kinase signaling pathways:
      • Growth factor signaling
      • PI3K/Akt/mTOR
      • MAPKs (ERK, p38, & JNK)
      • JAK/STAT signaling
    • Articles, resources, & advice
    EXPLORE NOW
    Product Description

    Afatinib is an irreversible inhibitor of epidermal growth factor receptor (EGFR) and ErbB2 (IC50s = 0.5 and 14 nM, respectively).1 It increases the cytotoxicity of adriamycin in a concentration-dependent manner in multidrug-resistant A549T lung cancer cells overexpressing P-glycoprotein.2 Afatinib (20 mg/kg) reduces tumor growth in ErbB2-amplified NCI-N87 and NUGC4 gastric cancer mouse xenograft models.3 Formulations containing afatinib have been used in the treatment of non-small cell lung cancer.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Eskens, F.A.L.M., Mom, C.H., Planting, A.S.T., et al. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br. J. Cancer 98(1), 80-85 (2008).

    2. Zhang, Y., Wang, C.-Y., Duan, Y.-J., et al. Afatinib decreases P-glycoprotein expression to promote adriamycin toxicity of A549T cells. J. Cell. Biochem. 119(1), 414-423 (2018).

    3. Yoshioka, T., Shien, K., Namba, K., et al. Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer. Cancer Sci. 109(4), 1166-1176 (2018).